Kerendia
Approved July 9, the drug is primarily used for treating chronic kidney disease and cardiovascular damage tied to Type 2 diabetes. The drug competes against similar, comparatively inexpensive drugs.
Atogepant (Brand name to be determined)
Atogepant is poised to compete with six other drugs that combat chronic and episodic migraines in adults, but early trials suggest it could either be with or ahead of the pack in terms of efficacy. The drug is still awaiting FDA approval, which is expected during the third quarter of 2021.
Bylvay
The drug treats symptoms tied to progressive familial intrahepatic cholestasis. It was approved by the FDA on July 20.
Maralixibat (Brand name to be determined)
Maralixibat treats alagille syndrome, which can lead to liver disease or failure. The report cites “high unmet needs” for treatment, and both maralixibat and Bylvay are expected to be “first-in-class” and have high price points.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.